It is a known fact that CTLA-4 Ig abatacept blocks CD28-mediated T cell activation by binding to the costimulatory B7 ligands CD80/CD86 on APCs, and it is currently used for RA and other autoimmune diseases. Here, CD86 is linked to rheumatoid arthritis.